血栓形成
胞外囊泡
血小板
生物标志物
医学
血小板活化
细胞外小泡
临床试验
重症监护医学
生物信息学
心脏病学
内科学
微泡
生物
小RNA
基因
细胞生物学
生物化学
作者
Aleksandra Gąsecka,Anita N. Böing,Krzysztof J. Filipiak,Rienk Nieuwland
出处
期刊:Platelets
[Informa]
日期:2016-12-20
卷期号:28 (3): 228-234
被引量:46
标识
DOI:10.1080/09537104.2016.1254174
摘要
Arterial thrombosis is a major and global cause of human death and disability. Considering the socioeconomic costs of arterial thrombosis, identification of biomarkers to predict and detect arterial thrombosis at an early stage is an important public health goal. Platelet extracellular vesicles (PEV) are a new candidate biomarker of arterial thrombosis. PEV can be measured in biorepositories, thereby offering the possibility to validate PEV in multicenter clinical trials. PEV analysis has been hitherto hampered by lack of standardized methodology, but substantial technological improvements of PEV detection techniques have been achieved recently. However, before PEV emerge from research tools to clinical applications, a number of issues should be clarified. To facilitate validation of PEV as biomarkers of thrombosis, we discuss (i) whether PEV are useful as biomarkers of thrombosis, (ii) why previous conclusions on PEV concentrations, composition and functions require re-evaluation, and (iii) which questions have to be answered before PEV become clinically useful.
科研通智能强力驱动
Strongly Powered by AbleSci AI